Catalent Zydis® & OSDrC® OptiDoseTM Technologies
Catalent Pharma Solutions is the global leader drug development solutions and advanced delivery technologies for pharmaceutical, biologics and consumer health products.
Catalent Zydis® & OSDrC® OptiDoseTM Technologies
Catalent's Zydis® orally disintegrating tablet (ODT) fast-dissolve formulation, is a unique, freeze-dried oral dosage form that disperses instantly in the mouth, requiring no water. This may enhance the performance and may also contribute towards better patient compliance.
With more than 20 products launched in 50 countries, Zydis is the world's best in class ODT technology. Whether to advance pharmacokinetics through pre-gastric absorption, improve patient compliance, or add marketing advantage to a valued brand, Catalent's customers draw on Zydis fast dissolve technology to potentially enhance investment value and accelerate a product’s potential.
Catalent’s OSDrC® OptiDose™ is an innovative, flexible core tableting technology that enables the formulation and manufacturing of single or multi-cored tablets with differentiated controlled release functionality and a range of unique dose forms, including fixed dose combination tablets.
With shown improvement in mass variability between layers, OptiDose offers tablet design, minimising cross-layer interaction and improving product stability.
In 2014, Catalent will celebrate 80 years of softgel manufacturing and has continually delivered innovation with specialised global manufacturing and innovative technological enhancements such as gelatin-free encapsulation, chewable softgels and enteric coatings, to enable delayed-release of the active ingredient with targeted absorption.
Company name: Catalent Pharma Solutions
Website: www.catalent.com
E-mail:
info@catalent.com
Market Demands and Emerging Technologies Shape Outsourcing Models
June 5th 2025Trends in certain forms of drug delivery, as well as the emergence of artificial intelligence, are playing roles in evolving the nature of partnerships, but there are new types of partnerships gaining steam as well.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
The Role of On-Demand Manufacturing and Derisking in Accelerating Early Clinical Trial Success
June 4th 2025Small pharmaceutical companies are constantly seeking innovative solutions to streamline early clinical trials. Adaptive clinical trials offer important benefits to sponsors and patients, both from a commercial and ethical standpoint. These trials offer flexibility and efficiency, especially in the early stages, where trial protocols can be adjusted based on interim data, such as introducing new doses or modifying participant sample size. However, adjusting manufacturing demand during an adaptive trial can be complicated, and strict regulatory requirements present significant challenges. On-demand manufacturing provides a robust solution, allowing for real-time supply and demand adjustments and improved trial flexibility. This paper explores how on-demand manufacturing meets the operational needs of adaptive trials and aligns with regulatory expectations.
